143 related articles for article (PubMed ID: 2824812)
1. Intestinal trypsin can significantly modify antigenic properties of polioviruses: implications for the use of inactivated poliovirus vaccine.
Roivainen M; Hovi T
J Virol; 1987 Dec; 61(12):3749-53. PubMed ID: 2824812
[TBL] [Abstract][Full Text] [Related]
2. Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin.
Roivainen M; Hovi T
J Virol; 1988 Sep; 62(9):3536-9. PubMed ID: 2841503
[TBL] [Abstract][Full Text] [Related]
3. Improved distribution of antigenic site specificity of poliovirus-neutralizing antibodies induced by a protease-cleaved immunogen in mice.
Roivainen M; Montagnon B; Chalumeau H; Murray M; Wimmer E; Hovi T
J Virol; 1990 Feb; 64(2):559-62. PubMed ID: 1688625
[TBL] [Abstract][Full Text] [Related]
4. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines.
Zhaori G; Sun M; Faden HS; Ogra PL
J Infect Dis; 1989 Jun; 159(6):1018-24. PubMed ID: 2470831
[TBL] [Abstract][Full Text] [Related]
5. Antibody responses to antigenic sites 1 and 3 of serotype 3 poliovirus after vaccination with oral live attenuated or inactivated poliovirus vaccine and after natural exposure.
Herremans T; Reimerink JH; Kimman TG; van Der Avoort HG; Koopmans MP
Clin Diagn Lab Immunol; 2000 Jan; 7(1):40-4. PubMed ID: 10618274
[TBL] [Abstract][Full Text] [Related]
6. Persistence and class-specificity of neutralizing antibody response induced by trypsin-cleaved type 3 poliovirus in mice.
Roivainen M; Piirainen L; Hovi T
Vaccine; 1993; 11(7):713-7. PubMed ID: 7688171
[TBL] [Abstract][Full Text] [Related]
7. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of immunization with live attenuated and inactivated poliovirus vaccines.
Ogra PL
Ann N Y Acad Sci; 1995 May; 754():97-107. PubMed ID: 7625685
[TBL] [Abstract][Full Text] [Related]
9. Anomalous observations on IPV and OPV vaccination.
John TJ
Dev Biol (Basel); 2001; 105():197-208. PubMed ID: 11763328
[TBL] [Abstract][Full Text] [Related]
10. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains.
Kersten G; Hazendonk T; Beuvery C
Vaccine; 1999 Apr; 17(15-16):2059-66. PubMed ID: 10217607
[TBL] [Abstract][Full Text] [Related]
11. [Risk of introduction and spread of polioviruses in closed-type child-care facilities].
Romanenkova NI; Bichurina MA; Rozaeva NP; Kanaeva OI
Zh Mikrobiol Epidemiol Immunobiol; 2014; (6):90-5. PubMed ID: 25816521
[TBL] [Abstract][Full Text] [Related]
12. Randomised, controlled trial with the trypsin-modified inactivated poliovirus vaccine: assessment of intestinal immunity with live challenge virus.
Piirainen L; Stenvik M; Roivainen M; Eskola J; Beuvery EC; Hovi T
Vaccine; 1999 Mar; 17(9-10):1084-90. PubMed ID: 10195618
[TBL] [Abstract][Full Text] [Related]
13. A Cluster of Paralytic Poliomyelitis Cases Due to Transmission of Slightly Diverged Sabin 2 Vaccine Poliovirus.
Korotkova EA; Gmyl AP; Yakovenko ML; Ivanova OE; Eremeeva TP; Kozlovskaya LI; Shakaryan AK; Lipskaya GY; Parshina IL; Loginovskikh NV; Morozova NS; Agol VI
J Virol; 2016 Jul; 90(13):5978-88. PubMed ID: 27099315
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses.
Faden H; Modlin JF; Thoms ML; McBean AM; Ferdon MB; Ogra PL
J Infect Dis; 1990 Dec; 162(6):1291-7. PubMed ID: 2172403
[TBL] [Abstract][Full Text] [Related]
15. CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus.
Yang C; Shi H; Zhou J; Liang Y; Xu H
Vaccine; 2009 Nov; 27(47):6558-63. PubMed ID: 19729087
[TBL] [Abstract][Full Text] [Related]
16. Intestinal Immune Responses to Type 2 Oral Polio Vaccine (OPV) Challenge in Infants Previously Immunized With Bivalent OPV and Either High-Dose or Standard Inactivated Polio Vaccine.
Brickley EB; Strauch CB; Wieland-Alter WF; Connor RI; Lin S; Weiner JA; Ackerman ME; Arita M; Oberste MS; Weldon WC; Sáez-Llorens X; Bandyopadhyay AS; Wright PF
J Infect Dis; 2018 Jan; 217(3):371-380. PubMed ID: 29304199
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a poliovirus-binding inhibition assay as an alternative to the virus neutralization test.
Herremans MM; Reimerink JH; Ras A; Van Der Avoort HG; Kimman TG; Van Loon AM; Conyn-Van Spaendonck MA; Koopmans MP
Clin Diagn Lab Immunol; 1997 Nov; 4(6):659-64. PubMed ID: 9384285
[TBL] [Abstract][Full Text] [Related]
18. The outbreak of poliomyelitis in Finland in 1984-1985: significance of antigenic variation of type 3 polioviruses and site specificity of antibody responses in antipolio immunizations.
Hovi T
Adv Virus Res; 1989; 37():243-75. PubMed ID: 2557759
[No Abstract] [Full Text] [Related]
19. An Introduction to Poliovirus: Pathogenesis, Vaccination, and the Endgame for Global Eradication.
Minor PD
Methods Mol Biol; 2016; 1387():1-10. PubMed ID: 26983727
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
